Reuters
"....The court's ruling came in a challenge launched
by medical researchers and others to seven patents owned by or licensed
to Salt Lake City, Utah-based biotechnology company Myriad Genetics Inc
on two genes linked to breast and ovarian cancer.......
".....The compromise outcome, which had been
recommended to the justices by the Obama administration, will have less
impact on Myriad than if the court had barred patents for all types of
human genetic material. The Myriad patents in dispute will all expire by
2015, though the company said it holds other patents that will protect
its tests through 2018 and potentially beyond......
"....."Based on our initial review of the court's
decision, we expect it will open opportunities for Quest Diagnostics to
develop new testing services, including in the area of hereditary breast
cancer," Quest spokeswoman Wendy Bost said......
".....Myriad said the decision left intact 24 different
patents that relate to the BRACAnalysis test. Peter Meldrum, Myriad's
president and CEO, said the ruling ensures "strong intellectual property
protection for our BRACAnalysis test moving forward."......
The case is Association for Molecular Pathology v. Myriad Genetics, U.S. Supreme Court, No. 12-398.
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.